Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269650 | 1.00 | SCN9A (0.54) | SCN9ACACNA1CTACR1CYP3A4SCN10A | |
| SCHEMBL1270449 | 0.89 | SCN9A (0.54) | SCN9ACACNA1CCYP3A4SCN10ACTSS | |
| SCHEMBL1270451 | 0.89 | SCN9A (0.54) | SCN9ACACNA1CCYP3A4SCN10ACTSS | |
| SCHEMBL27564123 | 0.84 | TACR1 (0.50) | SCN9ACACNA1CTACR1CYP3A4SCN10A | |
| SCHEMBL27564125 | 0.83 | TACR1 (0.52) | SCN9ATACR1CTSSCTSKKLK5 | |
| SCHEMBL28310184 | 0.82 | KLK5 (0.54) | TACR1CTSSCTSKKLK5 | |
| SCHEMBL2583495 | 0.82 | KLK5 (0.54) | TACR1CTSSCTSKKLK5 | |
| SCHEMBL24309187 | 0.82 | TACR1 (0.55) | SCN9ATACR1CTSSCTSKKLK5 | |
| SCHEMBL29478098 | 0.82 | TACR1 (0.55) | SCN9ATACR1CTSSCTSKKLK5 | |
| SCHEMBL7842742 | 0.82 | TACR1 (0.55) | SCN9ATACR1CTSSCTSKKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888345-B2 | Benzaepinones as sodium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | TRPV1, TRPA1, KCNN1 | SCN9A 160/4885CACNA1C 13/4885TACR1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.